130 related articles for article (PubMed ID: 38832688)
1. [Interference of oral anti-Xa anticoagulants during monitoring of unfractionated heparin treatments: practical and future attitudes].
Melicine S; Maucorps L; Eschwège V; Carré J; Helley D; Gouin-Thibault I; Gendron N; Nédélec-Gac F; Mauge L
Ann Biol Clin (Paris); 2024 Jun; 82(2):129-138. PubMed ID: 38832688
[TBL] [Abstract][Full Text] [Related]
2. A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations.
Levito MN; Coons JC; Verrico MM; Szymkowiak A; Legler B; Dueweke EJ; Kane-Gill SL
Ann Pharmacother; 2021 May; 55(5):618-623. PubMed ID: 32885997
[TBL] [Abstract][Full Text] [Related]
3. DOAC-Remove to counteract the interference of anti-Xa oral anticoagulants on the monitoring of heparin.
Melicine S; Habay C; Ghammad W; Carré J; Diehl JL; Smadja DM; Gendron N; Helley D; Mauge L
Int J Lab Hematol; 2024 May; ():. PubMed ID: 38803134
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
5. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions.
Faust AC; Kanyer D; Wittkowsky AK
Am J Health Syst Pharm; 2016 Dec; 73(24):2037-2041. PubMed ID: 27919873
[TBL] [Abstract][Full Text] [Related]
6. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
[TBL] [Abstract][Full Text] [Related]
8. [Use of heparin calibrated anti-Xa assay for apixaban and rivaroxaban measurement in the context of regional telestroke activity].
Delassasseigne C; Leroux C; Renou P; Girard D; Lafargue A; Morel S; Belotti PT; Weinmann L
Ann Biol Clin (Paris); 2023 Jul; 81(3):269-279. PubMed ID: 37329142
[TBL] [Abstract][Full Text] [Related]
9. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
10. The Relationship between the Initial Anti-factor Xa Measurement and the Duration of Direct Oral Anticoagulant Influence in Patients Transitioning to Heparin.
Plum MD; Hedrick JN; Hockman R; Bazydlo L; Palkimas S
Pharmacotherapy; 2020 Sep; 40(9):880-888. PubMed ID: 32677060
[TBL] [Abstract][Full Text] [Related]
11. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
[TBL] [Abstract][Full Text] [Related]
12. The PiCT
Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
[TBL] [Abstract][Full Text] [Related]
13. Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.
Martin AC; Lessire S; Leblanc I; Dincq AS; Philip I; Gouin-Thibault I; Godier A
Clin Cardiol; 2018 May; 41(5):646-651. PubMed ID: 29532536
[TBL] [Abstract][Full Text] [Related]
14. Perils of Antithrombotic Transitions: Effect of Oral Factor Xa Inhibitors on the Heparin Antifactor Xa Assay.
Ahuja T; Yang I; Huynh Q; Papadopoulos J; Green D
Ther Drug Monit; 2020 Oct; 42(5):737-743. PubMed ID: 32433187
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
16. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
17. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
[TBL] [Abstract][Full Text] [Related]
18. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
19. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
20. Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: A retrospective review.
Smith AR; Dager WE; Gulseth MP
Am J Health Syst Pharm; 2020 Aug; 77(Suppl 3):S59-S65. PubMed ID: 32719867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
